Successful use of a selective serotonin reuptake inhibitor in a patient with multiple chemical sensitivities

被引：8
|
作者：
Andine, P
Ronnback, L
Jarvholm, B
机构：
[1] SAHLGRENS UNIV HOSP, INST CLIN NEUROSCI, DEPT NEUROL, S-41345 GOTHENBURG, SWEDEN
[2] NORRLAND UNIV HOSP, DEPT OCCUPAT MED, UMEA, SWEDEN
来源：
ACTA PSYCHIATRICA SCANDINAVICA | 1997年 / 96卷 / 01期
关键词：
citalopram; depression; multiple chemical sensitivities;
D O I：
10.1111/j.1600-0447.1997.tb09910.x
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
A 53-year-old man with multiple chemical sensitivities (MCS) received the selective serotonin reuptake inhibitor (SSRI) citalopram for treatment of depression. The treatment was successful and, in parallel to the remission of the depressive symptoms, all MCS symptoms vanished. This suggests that a subgroup of MCS patients may have an atypical depression, that they should be psychiatrically evaluated, and that antidepressive pharmacological treatment may be considered in cases of MCS.
引用
收藏
页码：82 / 83
页数：2
相关论文
共 50 条
  • [41] Do Selective Serotonin Reuptake Inhibitor Antidepressant Drugs Promote Atherosclerosis?
    Wang, Jintao
    Eitzman, Daniel T.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (05) : 978 - 979
  • [42] Chronic Intake of the Selective Serotonin Reuptake Inhibitor Fluoxetine Enhances Atherosclerosis
    Rami, Martina
    Guillamat-Prats, Raquel
    Rinne, Petteri
    Salvermoser, Melanie
    Ring, Larisa
    Bianchini, Mariaelvy
    Blanchet, Xavier
    Megens, Remco T. A.
    Doering, Yvonne
    Walzog, Barbara
    Soehnlein, Oliver
    Weber, Christian
    Faussner, Alexander
    Steffens, Sabine
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2018, 38 (05) : 1007 - 1019
  • [43] Selective serotonin reuptake inhibitor use and breast cancer survival: a population-based cohort study
    Busby, John
    Mills, Ken
    Zhang, Shu-Dong
    Liberante, Fabio Giuseppe
    Cardwell, Chris R.
    BREAST CANCER RESEARCH, 2018, 20
  • [44] Use of Selective Serotonin Reuptake Inhibitors and Upper Gastrointestinal Disease
    Itatsu, Tomoko
    Nagahara, Akihito
    Hojo, Mariko
    Miyazaki, Akihisa
    Murai, Toshio
    Nakajima, Mikako
    Watanabe, Sumio
    INTERNAL MEDICINE, 2011, 50 (07) : 713 - 717
  • [45] Parsing Risk for the Use of Selective Serotonin Reuptake Inhibitors in Pregnancy
    Yonkers, Kimberly A.
    AMERICAN JOURNAL OF PSYCHIATRY, 2009, 166 (03) : 268 - 270
  • [46] Serotonin-Norepinephrine Reuptake Inhibitor and Selective Serotonin Reuptake Inhibitor Use and Risk of Fractures: A New-User Cohort Study Among US Adults Aged 50 Years and Older
    Lanteigne, Amy
    Sheu, Yi-han
    Stuermer, Til
    Pate, Virginia
    Azrael, Deb
    Swanson, Sonja A.
    Miller, Matthew
    CNS DRUGS, 2015, 29 (03) : 245 - 252
  • [47] Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence
    Zhu, Jing
    Klein-Fedyshin, Michele
    Stevenson, James M.
    PHARMACOTHERAPY, 2017, 37 (09): : 1089 - 1104
  • [48] Pregnancy Complications and Neonatal Mortality in a Serotonin Transporter Null Mouse Model: Insight Into the Use of Selective Serotonin Reuptake Inhibitor During Pregnancy
    Domingues, Rafael R.
    Wiltbank, Milo C.
    Hernandez, Laura L.
    FRONTIERS IN MEDICINE, 2022, 9
  • [49] Selective serotonin reuptake inhibitor use patterns among commercially insured US pregnancies (2005-2014)
    Petersen, Julie M.
    Esposito, Daina B.
    Werler, Martha M.
    ARCHIVES OF WOMENS MENTAL HEALTH, 2021, 24 (01) : 155 - 164
  • [50] Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response
    Ji, Y.
    Biernacka, J.
    Snyder, K.
    Drews, M.
    Pelleymounter, L. L.
    Colby, C.
    Wang, L.
    Mrazek, D. A.
    Weinshilboum, R. M.
    PHARMACOGENOMICS JOURNAL, 2012, 12 (01) : 78 - 85
12345